Serving patients and  transforming lives

Antibody engineering for promising drugs

A hope for finding a better tomorrow

Innovative research.  Transformative results.

Pioneering treatments for unmet needs

Dedicated to providing quality of life

What we do

NovelMed, a privately-held biotechnology company, is developing novel humanized monoclonal antibodies for orphan diseases with a specific focus on blocking the Complement Alternative Pathway (AP) involved in the disease process.  Our humanized monoclonal antibodies prevent formation and deposition of C3b and C5b-9 generated via only AP. Our novel drug candidates are therefore selective for the AP. We intend to target AP-mediated chronic orphan diseases with large market potential. Over the last decade, we have generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates especially for orphan diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH), C3-Glomerulopathy (C3G), and Neuromyelitis Optica (NMO). We believe that our portfolio of therapeutic antibodies has the potential for a better safety and efficacy profile than currently marketed drugs.
learn more

Research & development

NovelMed has developed a game changing R&D strategy which enables the development of high potency humanized monoclonal antibodies that neutralize specific proteins and processes within the Complement Alternative Pathway.  Our portfolio of antibodies are filtered through a unique research pattern to identify best-fit candidates for further development in a drug. We have achieved remarkable success in advancing multiple antibodies that have a unique and superior mechanism of action compared to known alternative research and commercial programs. Our pre-clinical pharmacokinetic, safety and toxicity studies provide compelling evidence that these antibodies are likely to have a longer half-life and an excellent safety profile.  Our antibodies can be administered intravenously or subcutaneously therefore providing easier dosing. 
learn more

Product Pipeline

Explore our Science